CR Boya Bio-pharmaceutical Q1 2026: Revenue Down 40.1% YoY, Net Profit Drops 78.4%

Bulletin Express04-24

CR Boya Bio-pharmaceutical, a 30.48%-owned subsidiary of CHINARES PHARMA, reported a sharp contraction in first-quarter earnings for the period ended 31 March 2026.

Revenue fell to RMB 321.13 million, a 40.1% year-on-year decline from RMB 535.88 million. Net profit slipped 78.4% to RMB 30.03 million, down from RMB 139.29 million in the same period last year.

Operating cash outflow narrowed: net cash decreased by RMB 303.00 million versus a RMB 713.11 million outflow a year earlier. Cash and cash equivalents at quarter-end stood at RMB 220.61 million, down 62.3% from RMB 585.46 million a year ago.

Total assets edged down 2.5% from year-end 2025 to RMB 8.41 billion, while total liabilities dropped 20.6% to RMB 942.80 million. Owners’ equity inched up 0.3% to RMB 7.46 billion.

The quarterly figures are unaudited and prepared under PRC GAAP; they may be subject to adjustment during the annual audit. The data cover CR Boya Bio-pharmaceutical only and do not represent the consolidated results of CHINARES PHARMA.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183075945?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183075945","market":"us","top_or_hot":-1,"title":"CR Boya Bio-pharmaceutical Q1 2026: Revenue Down 40.1% YoY, Net Profit Drops 78.4%","media":"Bulletin Express","content":"<p>CR Boya Bio-pharmaceutical, a 30.48%-owned subsidiary of CHINARES PHARMA, reported a sharp contraction in first-quarter earnings for the period ended 31 March 2026.</p>\n<p>Revenue fell to RMB 321.13 million, a 40.1% year-on-year decline from RMB 535.88 million. Net profit slipped 78.4% to RMB 30.03 million, down from RMB 139.29 million in the same period last year.</p>\n<p>Operating cash outflow narrowed: net cash decreased by RMB 303.00 million versus a RMB 713.11 million outflow a year earlier. Cash and cash equivalents at quarter-end stood at RMB 220.61 million, down 62.3% from RMB 585.46 million a year ago.</p>\n<p>Total assets edged down 2.5% from year-end 2025 to RMB 8.41 billion, while total liabilities dropped 20.6% to RMB 942.80 million. Owners’ equity inched up 0.3% to RMB 7.46 billion.</p>\n<p>The quarterly figures are unaudited and prepared under PRC GAAP; they may be subject to adjustment during the annual audit. The data cover CR Boya Bio-pharmaceutical only and do not represent the consolidated results of CHINARES PHARMA.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Boya Bio-pharmaceutical Q1 2026: Revenue Down 40.1% YoY, Net Profit Drops 78.4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Boya Bio-pharmaceutical Q1 2026: Revenue Down 40.1% YoY, Net Profit Drops 78.4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-24 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CR Boya Bio-pharmaceutical, a 30.48%-owned subsidiary of CHINARES PHARMA, reported a sharp contraction in first-quarter earnings for the period ended 31 March 2026.</p>\n<p>Revenue fell to RMB 321.13 million, a 40.1% year-on-year decline from RMB 535.88 million. Net profit slipped 78.4% to RMB 30.03 million, down from RMB 139.29 million in the same period last year.</p>\n<p>Operating cash outflow narrowed: net cash decreased by RMB 303.00 million versus a RMB 713.11 million outflow a year earlier. Cash and cash equivalents at quarter-end stood at RMB 220.61 million, down 62.3% from RMB 585.46 million a year ago.</p>\n<p>Total assets edged down 2.5% from year-end 2025 to RMB 8.41 billion, while total liabilities dropped 20.6% to RMB 942.80 million. Owners’ equity inched up 0.3% to RMB 7.46 billion.</p>\n<p>The quarterly figures are unaudited and prepared under PRC GAAP; they may be subject to adjustment during the annual audit. The data cover CR Boya Bio-pharmaceutical only and do not represent the consolidated results of CHINARES PHARMA.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1183075945","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183075945","pubTimestamp":1777034614,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CR Boya Bio-pharmaceutical, a 30.48%-owned subsidiary of CHINARES PHARMA, reported a sharp contraction in first-quarter earnings for the period ended 31 March 2026. Revenue fell to RMB 321.13...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润博雅生物制药2026年第一季度：收入同比下降40.1%，净利润下降78.4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"CR Boya Bio-pharmaceutical, a 30.48%-owned subsidiary of CHINARES PHARMA, reported a sharp contraction in first-quarter earnings for the period ended 31 March 2026.\nRevenue fell to RMB 321.13 million, a 40.1% year-on-year decline from RMB 535.88 million. Net profit slipped 78.4% to RMB 30.03 million, down from RMB 139.29 million in the same period last year.\nOperating cash outflow narrowed: net cash decreased by RMB 303.00 million versus a RMB 713.11 million outflow a year earlier. Cash and cash equivalents at quarter-end stood at RMB 220.61 million, down 62.3% from RMB 585.46 million a year ago.\nTotal assets edged down 2.5% from year-end 2025 to RMB 8.41 billion, while total liabilities dropped 20.6% to RMB 942.80 million. Owners’ equity inched up 0.3% to RMB 7.46 billion.\nThe quarterly figures are unaudited and prepared under PRC GAAP; they may be subject to adjustment during the annual audit. The data cover CR Boya Bio-pharmaceutical only and do not represent the consolidated results of CHINARES PHARMA.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183075945","isCrawlerRequest":true}